In vitro susceptibility of recent antibiotic-resistant urinary pathogens to ertapenem and 12 other antibiotics

Abstract

In view of its significant antibiotic potency against antibiotic-resistant Enterobacteriaceae, ertapenem may constitute a good therapeutic alternative in urinary infections caused by these pathogens.

Community-acquired urinary tract pathogens and their resistance patterns in hospitalized children in southeastern Ontario between 2002 and 2006

“…Antibiotic resistance has also been a concern in Canada and internationally (7)(8)(9)(10)(11)(12)(13). Escherichia coli, the most prevalent urinary tract pathogen, has shown high resistance to commonly used antibiotics, such as amoxicillin and trimethoprimsulfamethoxazole (14)(15)(16)(17).…”

The Urinary System Infections caused by Extended-Spectrum-β-Lactamase-producing Escherichia coli and Klebsiella pneumoniae Strains

“…Carbapenems, such as imipenem and meropenem, are commonly used for the treatment of ESBL-positive and Gram-negative bacterial infections (1,3,18). Resistance rates of carbapenems have been reported between 0-11.1% (1,18). In our study, although no resistance was observed against imipenem and meropenem in E. coli and K. pneumoniae strains, the resistance rate of ertapenem was assessed as 1.9% and 3.8%, respectively.…”

“…In our study, although no resistance was observed against imipenem and meropenem in E. coli and K. pneumoniae strains, the resistance rate of ertapenem was assessed as 1.9% and 3.8%, respectively. Amikacin is the second most active antibiotic following Carbapenems (12,18). In our study, the resistance rates of Amikacin in ESBL-positive E. coli and K. pneumoniae strains were 13.2% and 3.8%, respectively.…”

“…Carbapenems are potent antibiotics which possess the broadest spectrum of activity. Carbapenems, such as imipenem and meropenem, are commonly used for the treatment of ESBL-positive and Gram-negative bacterial infections (1,3,18). Resistance rates of carbapenems have been reported between 0-11.1% (1,18).…”

Fosfomycin and Its Application in the Treatment of Multidrug-Resistant Enterobacteriaceae Infections

“…18,32 These issues have led to restricted therapeutic use of fosfomycin as a single agent. However, at the present time, when there is a shortage of antibiotic research and a dramatic development of antimicrobial resistance, [33][34][35][36][37][38][39][40][41][42] previous prescribing habits must be reconsidered and better use made of the old antimicrobial agents, like fosfomycin.…”